Full text

Turn on search term navigation

© 2019. This work is licensed under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Anti-CD138 immuno-PET thus has the potential to improve MM imaging, especially regarding lesions with low metabolic activity [10,11]. [...]it could also be considered as a companion agent for currently developed therapies targeting CD138 [12,13]. In this work, we report the preclinical evaluation of a novel PET imaging agent based on the 89Zr-labeled anti-mouse syndecan-1 mAb (9E7.4, IgG2a κ isotype) [19] in a subcutaneous model and a bone marrow disseminated MM model using desferrioxamine B (DFO) as chelator. High liver, spleen and intestines uptakes were observed at all the time points. Because of this 89Zr accumulation in bones, as early as 48 h PI, 24 h PI time-point seems the optimal one for immuno-PET imaging with this radio-immunoconjugate. 2.2.2. PET imaging with 89Zr-DFO-9E7.4 was performed 24 h, 48 h and 72 h PI (Figure 4). Besides the physiological uptakes also observed in the SC model, bone metastases were easily distinguished with excellent tumor-to-background ratios.

Details

Title
What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between 89Zr- and 64Cu-Labeled Anti-CD138 in a Preclinical Syngeneic Model
Author
Bailly, Clément; Gouard, Sébastien; Guérard, François; Chalopin, Benjamin; Carlier, Thomas; Faivre-Chauvet, Alain; Patricia Remaud-Le Saëc; Bourgeois, Mickaël; Chouin, Nicolas; Rbah-Vidal, Latifa; Tripier, Raphaël; Haddad, Ferid; Kraeber-Bodéré, Françoise; Bodet-Milin, Caroline; Chérel, Michel
Publication year
2019
Publication date
2019
Publisher
MDPI AG
ISSN
16616596
e-ISSN
14220067
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2332085565
Copyright
© 2019. This work is licensed under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.